Exploiting MEK Inhibitor-Mediated Activation of ERα for Therapeutic Intervention in ER-Positive Ovarian Carcinoma

While the clinical benefit of MEK inhibitor (MEKi)-based therapy is well established in Raf mutant malignancies, its utility as a suppressor of hyperactive MAPK signaling in the absence of mutated Raf or Ras, is an area of ongoing research. MAPK activation is associated with loss of ERα expression a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, June Y., Rodriguez-Gabin, Alicia, Samaweera, Leleesha, Hazan, Rachel, Goldberg, Gary L., Horwitz, Susan Band, McDaid, Hayley M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563537/
https://www.ncbi.nlm.nih.gov/pubmed/23390495
http://dx.doi.org/10.1371/journal.pone.0054103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563537/
https://www.ncbi.nlm.nih.gov/pubmed/23390495
http://dx.doi.org/10.1371/journal.pone.0054103

Ejemplares similares